Form 8-K - Current report:
SEC Accession No. 0001493152-24-007408
Filing Date
2024-02-21
Accepted
2024-02-21 16:30:46
Documents
16
Period of Report
2024-02-14
Items
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43434
2 ex14-1.htm EX-14.1 96844
  Complete submission text file 0001493152-24-007408.txt   376479

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lgst-20240214.xsd EX-101.SCH 3815
4 XBRL DEFINITION FILE lgst-20240214_def.xml EX-101.DEF 26691
5 XBRL LABEL FILE lgst-20240214_lab.xml EX-101.LAB 36844
6 XBRL PRESENTATION FILE lgst-20240214_pre.xml EX-101.PRE 25315
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5906
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41002 | Film No.: 24660113
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)